|Articles|July 28, 2016
Oncology-Focused Biotech Selects Medidata
Start-up biotech selects Medidata Rave for Phase I and II trials of its investigational compound to address solid tumors and blood cancers.
Advertisement
Forty Seven Inc., a Stanford University start-up biotech specializing in cancer immunotherapy, will use Medidata’s electronic data capture, management and reporting system Medidata Rave in two of its upcoming Phase I and Phase II trials. Forty Seven takes its name from CD47 tumor cell protein that its lead molecule, Hu5F9-G4-an experimental monoclonal cancer drug-to be tested in solid tumor and blood cancers.
Read the full
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
One Clinical: Working Together to Advance Trial Collaboration
2
Syneos Health Expands AI Ecosystem With Three New Platform Partnerships
3
ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma
4
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
5